AMAG Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AMAG AMAG Pharmaceuticals Inc
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Closing Price
$13.67
Day's Change
0.01 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.67
Day's Low
13.61
Volume
(Light)
Volume:
723,563

10-day average volume:
1,312,130
723,563

UPDATE: How the EU will speed up approval of eventual COVID-19 vaccine, in contrast to what has happened in U.S.

12:58 pm ET October 8, 2020 (MarketWatch)
Print

By Pierre Briançon

Regulator will start examining the data from laboratory, animal and human testing in real time

The European health regulator said on Tuesday (https://www.ema.europa.eu/en/news/ema-starts-second-rolling-review-covid-19-vaccine) it would launch a "rolling review" of the coronavirus vaccine being developed by Pfizer (PFE) and BioNTech (BNTX), days after it announced a similar decision for the competing vaccine of AstraZeneca (AZN.LN) and the University of Oxford.

- A rolling review means the regulator will start examining the data from laboratory, animal and human testing in real time, without waiting for the whole set to be submitted at the end of the so-called Phase 3 trials.

- "This does not mean that a conclusion can be reached yet on the vaccine's safety and effectiveness, as much of the evidence is still to be submitted to the committee," the European Medicines Agency said in its release.

- As it did in the AstraZeneca case (https://www.ema.europa.eu/en/news/ema-starts-first-rolling-review-covid-19-vaccine-eu), the EMA said it had launched the process because "preliminary results from nonclinical and early clinical studies in adults (...) suggest that the vaccine triggers the production of antibodies and T cells that target the virus."

(https://twitter.com/EMA_News/status/1313408032844533762)

- The chief executives of all major global pharmaceuticals companies pledged last month, in an unprecedented joint release (https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/biopharma-leaders-unite-to-stand-with-science.html), in response to pressure to speed up the research, to "continue to adhere to high scientific and ethical standards regarding the conduct of clinical trials" and "only submit [a vaccine] for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study."

Opinion:AstraZeneca's coronavirus vaccine setback shows why Big Pharma prefers to be safe than sorry. Which is good news (http://www.marketwatch.com/story/astrazenecas-coronavirus-vaccine-setback-shows-why-big-pharma-would-rather-be-safe-than-sorry-2020-09-09)

The outlook: The rolling review will save time on the approval process, but doesn't change anything to the clinical trials process, which will develop at pace. The regulator's decision isn't a political one, and contrary to what has happened in the U.S (http://www.marketwatch.com/story/trump-white-house-accedes-to-fdas-new-vaccine-safety-guidelines-11602016191)., there has been no pressure from European governments on the regulator to speed up the approval of vaccines currently being developed. The EMA insists in its release that it will wait for all the data from the completed trials before it makes a decision. But once they are in, the bureaucratic process of decision will be faster than it would have been for an ordinary drug.

Read:Second coronavirus wave could delay Europe's recovery: ECB President Lagarde (http://www.marketwatch.com/story/second-coronavirus-wave-could-delay-europes-recovery-ecb-president-lagarde-2020-10-06)

-Pierre Briançon; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 08, 2020 12:58 ET (16:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.